Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Leveraging NKG2D Ligands in Immuno-Oncology

29 Jul 2021

Abstract excerpt

Immune checkpoint inhibitors (ICI) revolutionized the field of immuno-oncology and opened new avenues towards the development of novel assets to achieve durable immune control of cancer. Yet, the presence of tumor immune evasion mechanisms represents a challenge for the development of efficient treatment options. Therefore, combination therapies are taking the center of the stage in immuno-oncology. Such...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Immune Cell Function and Interaction
Share to Immune cells in cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34394116
DOI: 10.3389/fimmu.2021.713158

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Leveraging NKG2D Ligands in Immuno-OncologyPMID 34394116Read ↗

Immunobiology and Conflicting Roles of the Human NKG2D Lymphocyte Receptor and Its Ligands in CancerSemantic proximity Read ↗

NKG2D signaling in cancer immunosurveillanceSemantic proximity Read ↗

The Role and Regulation of the NKG2D/NKG2D Ligand System in CancerSemantic proximity Read ↗

NKG2D and MICA/B shedding: a ‘tag game’ between NK cells and malignant cellsSemantic proximity Read ↗

NKG2D Ligands–Critical Targets for Cancer Immune Escape and TherapySemantic proximity Read ↗

Recent Progress in NKG2D CAR-NK Cells for Cancer ImmunotherapySemantic proximity Read ↗

NKG2D Ligands in Tumor Immunity: Two Sides of a CoinSemantic proximity Read ↗

MHC class I chain-related A: Polymorphism, regulation and therapeutic value in cancer.Semantic proximity Read ↗

Advances in NKG2D ligand recognition and responses by NK cellsSemantic proximity Read ↗

Soluble NKG2D ligand promotes MDSC expansion and skews macrophage to the alternatively activated phenotype.Semantic proximity Read ↗

Human NKG2D-ligands: cell biology strategies to ensure immune recognitionSemantic proximity Read ↗

Targeting Immune Checkpoints: Basic Signaling Pathways and Clinical Translation in Cancer TherapeuticsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.